Follow us on Twitter
twitter icon@FreshPatents


Antagonist patents

      

This page is updated frequently with new Antagonist-related patent applications.




 Compositions and methods for modulating and redirecting immune responses patent thumbnailnew patent Compositions and methods for modulating and redirecting immune responses
Provided herein are methods of modulating and redirecting an immune response. Compositions and methods for killing targeted cells in a cell population are also provided wherein, a cell population containing target cells expressing a target associated antigen and t cells are contacted with 1, 2, or more immune checkpoint antagonists and a multispecific t cell-redirecting agent that specifically binds the target associated antigen expressed on the target cells and specifically binds a t cell surface antigen..
Duke University


 Cd86 antagonist multi-target binding proteins patent thumbnailnew patent Cd86 antagonist multi-target binding proteins
This disclosure provides a multi-specific fusion protein composed of a cd86 antagonist binding domain and another binding domain that is an il-10 agonist, an hla-g agonist, an hgf agonist, an il-35 agonist, a pd-1 agonist, a btla agonist, a light antagonist, a gitrl antagonist or a cd40 antagonist. The multi-specific fusion protein may also include an intervening domain that separates the other domains.
Aptevo Research And Development Llc


 Growth hormone receptor agonists patent thumbnailnew patent Growth hormone receptor agonists
We disclose growth hormone fusion proteins that have increased in vivo stability and activity; nucleic acid molecules encoding said proteins and methods of treatment of growth hormone related diseases that would benefit from growth hormone agonists or antagonists.. .
Asterion Limited


 Superagonists and antagonists of interleukin-2 patent thumbnailnew patent Superagonists and antagonists of interleukin-2
Novel human interleukin-2 (il-2) muteins or variants thereof, and nucleic acid molecules and variants thereof are provided. Methods for producing these muteins as well as methods for stimulating the immune system of an animal are also disclosed.
The Board Of Trustees Of The Leland Stanford Junior University, Office Of The General Counsel


 Use of arylalkanolamines as sigma-1 receptor antagonists patent thumbnailnew patent Use of arylalkanolamines as sigma-1 receptor antagonists
The present invention relates to the use of arylalkanolamine compounds with sigma-1 receptor antagonist activity. In particular, the said arylalkanolamine compounds are useful in the treatment of conditions selected from the abuse of psychotropic substances such as cocaine or amphetamines, pain and cancer..
Università Degli Studi Di Pavia


 Tin-117m somatostatin receptor binding compounds and methods patent thumbnailnew patent Tin-117m somatostatin receptor binding compounds and methods
Tin-117m somatostatin analogues or antagonist are used to treat tumors and symptoms associated with these tumors which express somatostatin receptors, such as gastroenteropancreatic neuroendocrine tumors. The tin-117m somatostatin receptor binding compounds can be administered at a dosage which is effectively apoptotic and not necrotic.
Serene, Llc


 Compositions and methods of treating t cell mediated disorder patent thumbnailnew patent Compositions and methods of treating t cell mediated disorder
A method of generating a cd4+foxp3+ treg cell, the method includes administering at least one complement antagonist to a naive cd4+ t cell at an amount effective to substantially inhibits c3a receptor (c3ar) and/or c5a receptor (c5ar) signal transduction in the cd4+ t cell, induce tgf-β1 expression of the cd4+ t cell, and induce differentiation of the of the naive cd4+ t cell into a cd4+foxp3+ treg cell.. .
Case Western Reserve University


 Compositions and methods for administering galectin antagonists patent thumbnailnew patent Compositions and methods for administering galectin antagonists
The invention provides methods for the treatment of diseases and conditions relating to galectin 3 using a galectin-3 inhibitor, such as a modified pectin (e.g., gcs-100). Also described are methods for conjoint therapy, and methods for assessing and/or monitoring the effects of a galectin-3 inhibitor, e.g., to adapt the dosing regimen of the inhibitor during therapy..
La Jolla Pharmaceutical Company


 Use of nk-1 receptor antagonists for treating hypomagnesemia, neurogenic inflammation, and cardiac dysfunction associated with egfr-blocking drugs patent thumbnailnew patent Use of nk-1 receptor antagonists for treating hypomagnesemia, neurogenic inflammation, and cardiac dysfunction associated with egfr-blocking drugs
The present disclosure provides methods for alleviating or preventing the negative physiological side effects associated with the administration of egfr blocking therapeutics. The disclosure provides, inter alia, methods for treating or preventing: hypomagnesemia, cardiac dysfunction, and skin lesions, which are induced by egfr blocking drugs, by administering an nk-1 receptor antagonist..
The George Washington University


 Abuse-resistant controlled-release opioid dosage form patent thumbnailnew patent Abuse-resistant controlled-release opioid dosage form
Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist such as naloxone at a level above that needed to suppress the euphoric effect of the opioid, if the combination were crushed to break the controlled release properties causing the opioid and opioid antagonist to be released as a immediate release product as a single dose. The controlled release nature of the table prevents the accumulation of orally effective amounts of opioid antagonist when taken normally.
Purdue Pharma L.p.


new patent

Abuse-resistant controlled-release opioid dosage form

Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist such as naloxone at a level above that needed to suppress the euphoric effect of the opioid, if the combination were crushed to break the controlled release properties causing the opioid and opioid antagonist to be released as a immediate release product as a single dose. The controlled release nature of the table prevents the accumulation of orally effective amounts of opioid antagonist when taken normally.
Purdue Pharma L.p.

new patent

Method for inhibiting tumor metastasis

A leukotriene c4 and d4 antagonist is used to inhibit tumor metastasis by acting to inhibit tumor cell adhesion to endothelial cells, therby preventing tumor cell extravasation.. .
Inflammation Research Center Company Ltd.

Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies

The invention provides compositions and methods for treating her2-postitive cancers. The method comprising administering a pd-1 axis binding antagonist and an antibody that targets her2..
Genentech, Inc.

Spiro-oxazolones

The present invention provides spiro-oxazolones, which act as v1a receptor modulators, and in particular as v1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The present compounds are useful as therapeutics acting peripherally and centrally in the conditions of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag..
Hoffmann-la Roche Inc.

Substituted thiazole or oxazole p2x7 receptor antagonists

The present invention refers to novel substituted thiazole and oxazole compounds of formula (i) having p2x7 receptor (p2x7) antagonistic properties. The compounds are useful in the treatment or prophylaxis of diseases associated with p2x7 receptor activity in animals, in particular humans..
Axxam S.p.a.

Farnesoid x receptor antagonists

Provided herein are farnesoid x receptor (fxr) antagonists having the structure of formula (i), and pharmaceutical compositions comprising the compound of formula (i) and a pharmaceutically acceptable excipient. Also provided are methods of antagonizing fxr, and methods of treating metabolic disease in a subject in need thereof, comprising administering an effective amount of the fxr antagonists of formula (i) to a subject..
City Of Hope

Plant nutrient composition for synergistically increasing flavors and improving textures of fruits and fruit vegetables and method therefor

A plant nutrient composition of the present invention can produce high-quality fruits or fruit vegetables which cause substantially no chemical damage, have no antagonistic action of each component in crops, synergistically increase inherent flavors of fruits through interactions of nitrogen and calcium, and improve textures, by performing foliage spray through a specific range of weight ratio of total nitrogen and water-soluble calcium, the spray concentration, and the spray amount when fruits or fruit vegetables are cultivated.. .
Jahngryu Industries.,ltd

Pegylated growth hormone antagonists

A composition that is a human growth hormone receptor antagonist comprising human growth hormone receptor antagonist g120k, wherein at least one amino acid of human growth hormone receptor antagonist g120k has been mutated to cysteine; and a polytethylene glycol molecule (peg) conjugated to each cysteine residue in the human growth hormone receptor antagonist g120k mutant.. .

Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders

Provided herein, for example, are methods generally relating to the expansion and/or regeneration of central nervous system (cns) cells, such as nerve cells, astrocytes and oligodendrocytes, using an activator of cereblon (crbn), such as an inhibitor of a crbn substrate or downstream protein. Also provided herein, for example, are methods related to the expansion of neural stem cells, neural progenitor cells, or neural precursor cells and/or differentiation of these cells into cns cells using a brd7 antagonist, ikaros antagonist, or crbn activator.
Celgene Corporation

Serotonin 2c receptor antagonists to prevent and treat stress-related trauma disorders

The invention relates to methods for preventing stress-associated disorders. These disorders may be treated with a serotonin 2c receptor (5-ht2cr) antagonist prior to, during, or following a stress-related event.
Massachusetts Institute Of Technology

Compositions for affecting weight loss

Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (mc3-r) or a melanocortin 4 receptor (mc4-r) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance α-msh activity..
Orexigen Therapeutics, Inc.

Peripheral opioid receptor antagonists and uses thereof

Wherein x−, r1, and r2 are as defined herein, and compositions thereof.. .

Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses

The invention relates to the field of medicine, in particular to the field of veterinary medicine. The invention specifically relates to muscarinic antagonists (including long acting muscarinic antagonists (lamas)) for the treatment of airway disease, such as pulmonary disease, preferably recurrent airway obstruction (rao), summer pasture associated obstructive pulmonary disease (spaopd), and inflammatory airway disease (iad) in animals, preferably equines such as horses..
Boehringer Ingelheim Vetmedica Gmbh

Method of treating or inhibiting the development of brain inflammation and sepsis

A leukotriene c4 and d4 antagonist is used to treat or inhibit brain inflammation and sepsis by acting to inhibit increased capillary permeability and white blood cell extravasation. Potential candidate compounds can be screened in a non-human mammal before or after administration of an inflammation inducing agent into the subarachnoid space by determining their ability to inhibit increased capillary permeability and white blood cell extravasation..
Inflammation Research Center Company Ltd.

Methods and pharmaceutical compositions for the treatment of heart failure

The present invention relates to an inhibitor of ngal gene expression or a ngal antagonist for use in the prevention or the treatment of heart failure.. .
Institut National De La Sante Et De La Recherche M Edicale (inserm)

Combination treatment for multiple sclerosis

The present application provides evidence that a combined blockade against alpha-4 integrin and mcam is more effective than against either molecule alone. In consequence, the invention provides methods of combination treatment in which both an antagonist of alpha-4 integrin and an mcam antagonist are administered to a subject having or at risk of multiple sclerosis or other autoimmune disease..
University Of Munster

Azaspiro derivatives as trpm8 antagonists

The present invention relates to azaspiro derivatives of the formula (i) or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the trpm8 receptor.. .
Raqualia Pharma Inc.

Benzene sulfonamides as ccr9 inhibitors

The present invention relates to compounds useful as ccr9 modulators, to compositions containing them, to methods of making them, and to methods of using them. In particular, the present invention relates to compounds capable of modulating the function of the ccr9 receptor by acting as partial agonists, antagonists or inverse agonists.
Norgine B.v.

Compounds useful as ccr9 modulators

The present invention relates to compounds useful as ccr9 modulators, to compositions containing them, to methods of making them, and to methods of using them. In particular, the present invention relates to compounds capable of modulating the function of the ccr9 receptor by acting as partial agonists, antagonists or inverse agonists.
Norgine B.v.

Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists

The invention provides methods of treating or delaying progression of cancer in an individual comprising administering to the individual an anti-human ox40 agonist antibody and an anti-pdl1 antibody. In some embodiments, the anti-human ox40 agonist antibody is administered in a dose selected from about 0.8 mg, about 3.2 mg, about 12 mg, about 40 mg, about 80 mg, about 130 mg, about 160 mg, about 300 mg, about 320 mg, about 400 mg, about 600 mg, and about 1200 mg, and the anti-pdl1 antibody is administered at a dose of about 800 mg or about 1200 mg..
Genentech, Inc.

Methods and compositions for inhibiting mitochondrial trafficking

Methods for reducing, inhibiting or preventing cancer metastasis comprise blocking the movement of mitochondria within a cancer cell. Other methods involve interrupting or preventing oxidative phosphorylation pathways or respiration pathways in the cancer cell.
The Wistar Institute Of Anatomy And Biology

Thromboxane receptor antagonists in aerd/asthma

The present invention is directed to methods of treating aerd (aspirin exacerbated respiratory disease) and/or asthma via the administration of a thromboxane receptor antagonist to a patient in need thereof.. .
Cumberland Pharmaceuticals, Inc.

Use of an il-17/il-23 bispecific antibody for treating inflammation

The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of il-17a, il-17f, and il-23. Antagonists include antibodies and antibody fragments that bind il-23 and that bind il-17a or il-17f, such as antibodies that are cross-reactive for il-17a and il-17f.
Zymogenetics, Inc.

Iap antagonists

There are disclosed compounds that modulate the activity of inhibitors of apoptosis (iaps), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.. .
Bristol-myers Squibb Company

Methods for reducing anxiety and impulsivity in subjects initiating treatment with serotonin reuptake inhibitors

The present invention provides compositions and uses thereof for reducing anxiety and/or impulsivity, including, for example, suicidality, in a subject undergoing treatment with a serotonin reuptake inhibitor (sri) comprising administering to the subject an effective amount of a sri and an effective amount of a 5-ht1a receptor partial agonist/antagonist. In addition, the present invention provides dosing regimens for various ssris which can also reduce anxiety and/or impulsivity, including, for example, suicidality in a subject undergoing treatment with an ssri.
The Johns Hopkins University

Pharmaceutical composition

Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided.
Alpharma Pharmaceuticals Llc

Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto

The present invention also relates to the method of prophylaxis or treatment of 5-ht2a serotonin receptor mediated disorders in combination with a dopamine d2 receptor antagonist such as haloperidol, administered separately or together.. .

Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration

Inhalation solutions for administration of beta 2-agonists or combinations of muscarinic antagonists and beta 2-agonists for the treatment of breathing disorders, such as copd, are provided. The inhalation solutions are administered by nebulization, particularly with a high efficiency nebulizer..
Sunovion Respiratory Development, Inc.

Method for modulating plant growth

The present invention provides a method for modulating non-root plant growth of a plant employing plant regulatory peptides, nucleotides encoding same, receptors therefor, binding agents thereof or agonists or antagonists thereof. Such methods encompass methods for increasing shoot growth or accelerating shoot development of plants, whereby said plants: yield a greater amount of above-ground plant matter than an untreated or wild-type plant grown under the same conditions; grows faster than an untreated or wild-type plant grown under tire same conditions; develops faster than an untreated or wild-type plant grown under the same conditions.
The Australian National University

Organ preconditioning, arrest, protection, preservation and recovery

The present invention relates to a method for reducing electrical disturbance of a cell's resting membrane potential comprising administering an effective amount of a composition comprising an effective amount of a local anaesthetic and of one or more of a potassium channel opener, an adenosine receptor agonist, an anti-adrenergic, a calcium antagonist, an opioid, an no donor and a sodium hydrogen exchange inhibitor.. .
Hibernation Therapeutics, A Kf Llc

Identification of cxcr8, a novel chemokine receptor

Method of treating a subject for a disorder that correlates to increased cxcr8 signaling. The method includes disrupting the activation of receptor cxcr8 by ligand cxcl17 in the subject.
The Regents Of The University Of California

Compositions comprising antibodies to lingo or fragments thereof

Endogenous lingo-1 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous lingo-1 function, such anti-lingo-1 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction.
Biogen Ma Inc.

Novel a4b7 peptide dimer antagonists

The invention relates to disulfide-rich dimer molecules which inhibit binding of α4β7 to the mucosal addressin cell adhesion molecule (madcam) in vivo, and show high selectivity against α4β1 binding.. .
Protagonist Therapeutics, Inc.

Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists

The invention relates to crystalline forms of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone, processes for the preparation thereof, pharmaceutical compositions containing such crystalline forms, pharmaceutical compositions prepared from such crystalline forms, and their use as a medicament, especially as orexin receptor antagonists.. .
Actelion Pharmaceuticals Ltd

2-pyridyloxy-4-methyl orexin receptor antagonists

The present invention is directed to 2-pyridyloxy-4-methyl compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-4-methyl compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
Merck Sharp & Dohme Corp.

Thromboxane receptor antagonists

The invention relates to novel chemical entities that act as thromboxane (tx) a2 receptor, or t prostanoid receptor (tp), antagonists and to their use in the treatment of human diseases in which thromboxane (tx) a and of all other agents that act as incidental ligands of tp, including the endoperoxide prostaglandin (pg)g2/pgh2, 20-hydroxyeicosatetraenoic acid (20-hete) and the free-radical derived isoprostanes (e.g., 8-iso-prostaglandin (pg)f2α), play a role. Compounds of the invention preferably include a benzenesulfonyl urea in which the benzene is substituted by a substituted biphenylyloxy group (e.g., at the 2 position) and by a nitrile group (e.g., at the 5 position), which compounds show promising results as tp-isoform selective tp antagonists..
University College Dublin, National University Of Ireland, Dublin

Pharmaceutical compositions for anesthesiological applications

Pharmaceutical compositions and methods are described, the compositions comprising a benzodiazepine-based compound, a nmda antagonist, a β-blocker and antiemetic. Methods for fabricating the compositions and using them for anesthesiological applications are also described..
Imprimis Pharmaceuticals, Inc.

Methods for treating parkinson's disease

The invention pertains to a method of treating parkinson's disease (pd) in a mammal, comprising administering a first pharmaceutical agent and a second pharmaceutical agent, wherein the first pharmaceutical agent is an antagonist of the adenosine receptor 2 (a2a) and the second pharmaceutical agent is an antagonist of the n-methyl-d-aspartate (nmda) receptor subtype nr2b.. .
Ucb Biopharma Sprl



Antagonist topics:
  • Antagonist
  • Recurrence
  • Proliferative Disorder
  • Proliferative
  • Antibodies
  • Progesterone
  • Dicyclomine
  • Scopolamine
  • Extracellular
  • Pharmaceutically Acceptable Salt
  • Metalloprotein
  • Nucleic Acids
  • Polynucleotide
  • Nucleic Acid
  • Monoclonal


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Antagonist for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Antagonist with additional patents listed. Browse our RSS directory or Search for other possible listings.


    1.381

    file did exist - 2376

    2 - 1 - 51